Jubilant rejigs North American operations

By Phil Taylor

- Last updated on GMT

Related tags: North america

Jubilant Organosys, India's largest custom research and manufacturing services (CRAMS) provider, has reorganised its business in North America in the wake of its recent acquisitions of HollisterStier Laboratories and Draxis Specialty Pharmaceuticals.

The move bundles the two companies’ activities into two discrete groups, each headed up by a newly-appointed chief executive.

Jean Pierre Robert has been appointed CEO of a division called Specialty Pharmaceutical, which will combine the radiopharmaceuticals business of Draxis with the allergy extracts business of HollisterStier Laboratories. In July 2007 he was appointed president of Draxis Specialty Pharmaceuticals.

Meanwhile, Marcelo Morales has been appointed as the CEO for the contract manufacturing division, with responsibility for the sterile injectables manufacturing arm of HollisterStier and the sterile injectable, semi- solids and solid dose manufacturing operations of Draxis.

This strategic move will result in cohesive operations​,” said Jubilant in a statement. Specialty Pharmaceuticals becomes a group focused on research and development and product innovation, while the revamped Contract Manufacturing unit “consolidates Jubilant's leadership in the areas of both sterile and non-sterile contract manufacturing by leveraging multi-site capabilities.​”

Jubilant bought US firm Hollister-Stier Laboratories for $122.5m last year in what at the time represented one of the largest overseas acquisitions by an Indian company in the CRAMS sector. That was swiftly followed by another record when it snapped up Canadian Draxis Health for $255m.

Bringing Draxis and Hollister-Stier into the Jubilant fold gave the Indian company a strong position in the North American contract manufacturing market, especially in the area of small volume parenteral drugs which is a big focus for the firm.

Draxis also added to Jubilant's capacity in non-sterile products, such as solid oral and semi-solid dosage forms, and placed Jubilant within the top five sterile manufacturing companies in North America, according to the firm.

"This strategic realignment will enable us to drive value for our customers through synergistic operations​," commented Jubilant Organosys co-chairmen, Shyam and Hari Bhartia.

"With a focus on continuous innovation, expansion of service offerings and locations we ensure that our customers receive the desired level of quality, flexibility and expertise to meet the market demands​," they added.

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-May-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Related suppliers

Follow us


View more